Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 0575/64080/JPW/ALB	Serial No. 09/872,185
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant David Stern, et al.	
	Filing Date June 1, 2001	Group 1641

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

85		Baynes, J. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412. (Exhibit 1);
		Behl, C., et al. (1994). Hydrogen Peroxide Mediates Amyloid β Protein Toxicity.Cell 77, 817-827. (Exhibit 2);
		Vlassara, H., et al. (1994). Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 70: 138-151. (Exhibit 3);
		Schmidt, A.M., SD Yan, and D. Stern.(1995). The Dark Side of Glucose (News and Views). Nature Medicine 1:1002-1004 . (Exhibit 4);

EXAMINER [signature] DATE CONSIDERED 6/3/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 0575/64080/JPW/ALB	Serial No. 09/872,185
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicants David Stern, et al.	
	Filing Date June 1, 2001	Group 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Schmidt, A.M., Vianna,M., Gerlach, M., Brett, J., Ryan, J., Kao, J., Esposito, C., Hegarty, H., Hurley, W., Clauss, M., Wang, F., Pan, Y.C., Tsang, T.C., and Stern, D. (1992). Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface. J.Biol. Chem. 267,14987-14997.(Exhibit 5);
		Brett, J. et al., (1993). Survey of the distribution of a newly-characterized receptor for AGEs in tissues. *Am. J. Pathol.* 143:1699-1712. (Exhibit 6);
		Hori O., J. Brett, T. Slattery, R. Cao, J.Zhang, J. Chen, M. Nagashima, D. Nitecki, J. Morser, D. Stern, A.M. Schmidt.(1995). The Receptor for Advanced Glycation Endproducts (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J.Biol. Chem. 270:25752-25761. (Exhibit 7);
		Schmidt, A-M. et al. (1994). Cellular Receptors for Advanced Glycation Endproducts. *Arterioscler. Thromb.*, 14:1521-1528. (Exhibit 8);
		Schmidt, A-M. et al. (1994). Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. *Proc. Natl. Acad. Sci. (USA)*, 91:8807-8811. (Exhibit 9);
		Sell, D., and Monnier, V. (1989). Structure elucidation of a senescene cross-link from human extracellular matrix: implication of pentoses in the aging process.J.Biol. Chem. 10 264, 21597-21602. (Exhibit 10);
		Giardino, I. et al. (1994). Nonenzymatic glycosylation in Vitro and in bovine endothelial cells after basic fibroblast growth factor activity. J. Clin. Invest. 94:110-117. (Exhibit 11).

EXAMINER	DATE CONSIDERED 6/3/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 0575/64080/JPW/ALB	Serial No. 09/872,185
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicants **David Stern et al.**	
	Filing Date **June 1, 2001**	Group 1641

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C	Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts. Circulation Supplement. Abstract 3079. (Exhibit 12);
		Wautier, J.-L., et al. (1996). Interaction of diabetic erythrocytes bearing advanced glycation endproducts with the endothelial receptor AGE induces generation of reactive oxygen intermediates and cellular dysfunction. Circulation Supplement 94(8):4139. (Exhibit 13);
		Wu J, Rogers L, Stern D, Schmidt AM and Chiu DTW.(1997). The soluble receptor for Advanced Glycation Endproducts (sRAGE) ameliorates impaired wound healing in diabetic mice. Plastic Surgery Research Council. Abstract #77. p. 43. (Exhibit 14);
		Schmidt, A-M. et al. (1994). Cellular receptors for advanced glycation end products. *Arterioscler. Thromb.*, 14:1521-1528. t. 92:2155-2168. (Exhibit 15);

EXAMINER	DATE CONSIDERED 6/3/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.